$Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment$

Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment

Background. Currently, treatment of recurrent / refractory chronic lymphocytic leukemia (CLL) involves the appointment of regimens with innovative drugs, which include ibrutinib and a combination of venetoclax and rituximab. Wherein said combination provides continuing over time high frequency eradi...

Full description

Bibliographic Details
Main Authors:	A. V. Rudakova, E. A. Stadnik
Format:	Article
Language:	Russian
Published:	ABV-press 2020-04-01
Series:	Onkogematologiâ
Subjects:	chronic lymphocytic leukemia venetoclax rituximab ibrutinib cost minimization budget impact analysis
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/408

Similar Items

Prognosis and new therapeutic approaches in chronic lymphocytic leukemia treatment
by: Otašević Vladimir, et al.
Published: (2019-01-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Ferrarini, I., et al.
Published: (2022)

RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?
by: Antonio Cuneo, et al.
Published: (2019-02-01)

MODERN APPROACHES TO TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
by: A. A. Danilenko, et al.
Published: (2020-12-01)

Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs
by: Candida Vitale, et al.
Published: (2020-01-01)

EXPERIENCE WITH IBRUTINIB IN PATIENTS WITH REFRACTORY AND RECURRENT B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
by: T. V. SOROKINA, et al.
Published: (2017-06-01)

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

Pharmacists’ Role in Managing Patients with Chronic Lymphocytic Leukemia
by: Kevin Y. Chen, et al.
Published: (2020-03-01)

Prospective analysis of efficacy and safety of BR regime in the first-line treatment of chronic lymphocytic leukemia
by: E A Stadnik, et al.
Published: (2016-12-01)

EFFECTIVENESS OF VENETOСLAX IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (LITERATURE REVIEW)
by: V. V. Strugov, et al.
Published: (2018-02-01)

Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
by: EA Stadnik, et al.
Published: (2018-01-01)

The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients
by: NV Kurkina, et al.
Published: (2019-05-01)

Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
by: Lukáš Smolej, et al.
Published: (2021-06-01)

Current treatment of chronic lymphocytic leukemia. New opportunities and new difficulties
by: O S Samoylova
Published: (2016-12-01)

Infections in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib: Incidence and Predisposing Factors
by: EA Dmitrieva, et al.
Published: (2019-09-01)

Frontline therapies for untreated chronic lymphoid leukemia
by: Delong Liu, et al.
Published: (2019-08-01)

Management of atypical chronic lymphocytic leukemia presenting with extreme leukocytosis
by: Ramya Muddasani, et al.
Published: (2020-05-01)

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre‐ibrutinib era: Incidence and risk factors
by: Peter Georgantopoulos, et al.
Published: (2019-05-01)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
by: Huber H, et al.
Published: (2017-02-01)

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
by: Francesca Romana Mauro, et al.
Published: (2021-06-01)

Pharmacoeconomic analysis of the use of ibrutinib in therapy of the first line of a chronic lymphocytic leukaemia for patients with 17p deletion
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant
by: Samip Master, et al.
Published: (2017-06-01)

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
by: Maria Tariq Siddiqui, et al.
Published: (2021-01-01)

Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
by: EA Nikitin, et al.
Published: (2017-07-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
by: Maria Cristina Puzzolo, et al.
Published: (2021-04-01)

BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
by: Lorenzo Falchi, et al.
Published: (2016-02-01)

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
by: Matteo Piccini, et al.
Published: (2021-04-01)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
by: Bartosz Puła, et al.
Published: (2019-11-01)

Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
by: Casado LF, et al.
Published: (2016-09-01)

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
by: Maurizio Cavallari, et al.
Published: (2017-01-01)

Pharmacoeconomic aspects of biosimilars
by: A A Tryakin, et al.
Published: (2017-01-01)

Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report
by: Guillaume Beziat, et al.
Published: (2020-02-01)

Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017
by: Stefano Molica
Published: (2017-08-01)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
by: Ilaria Del Giudice, et al.
Published: (2019-08-01)

Oral Cryptococcosis in a Patient with Chronic Lymphocytic Leukemia
by: Sachin Patel, et al.
Published: (2016-09-01)

Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report
by: Thuy-Hong Le, et al.
Published: (2020-02-01)

Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia
by: YuV Mirolyubova, et al.
Published: (2018-04-01)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
by: Benjamin Arthurs, MD, et al.
Published: (2017-01-01)